-
Views
-
Cite
Cite
Marija Zeremski, Rositsa B. Dimova, Samantha Benjamin, Marina S. Penney, Martyn C. Botfield, Andrew H. Talal, Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus–Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin, The Journal of Infectious Diseases, Volume 211, Issue 11, 1 June 2015, Pages 1795–1799, https://doi.org/10.1093/infdis/jiu807
- Share Icon Share
Abstract
We assessed peripheral and liver CXCL10 levels in 15 patients treated with telaprevir/pegylated interferon/ribavirin. Induction of peripheral CXCL10 messenger RNA (mRNA) peaked (mean fold-induction [±SD], 3.1 ± 1.9) between treatment hour 6 and day 2, while induction of intrahepatic CXCL10 mRNA peaked (mean fold-induction [±SD], 1.3 ± 0.54) at hour 10 or day 4. Peripheral CXCL10 levels were higher at treatment hour 10 (P = .032) and day 2 (P = .009) in patients with undetectable virus 2 weeks after treatment initiation. Treatment hour 10 (P = .023) and peak (P = .034) intrahepatic CXCL10 levels were also higher in these patients. CXCL10 did not distinguish treatment responders from nonresponders. In conclusion, CXCL10 identified very rapid virological response in patients treated with a direct-acting antiviral.
Clinical Trials Registration. NCT00892697.